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Summary We investigated 5-azacytidine and five of its analogues for: (1) carcinogenicity, in the male Fischer
rat; (2) toxicities using changes in rat weights in vivo and a cytotoxicity assay in vitro; and (3) haemoglobin
gene expression, using minor haemoglobin synthesis in sheep, mice and rats. 5-Azacytidine was found to be a
complete carcinogen. It increased the incidence of testicular tumours as well as non-testicular tumours in rats
treated for 12 months. 5-Azacytidine also had hepatic tumour promoting properties and was able to induce
transplacental carcinogenesis when administered to pregnant rats on day 21 of timed pregnancies. None of the
other 5 analogues that were tested appeared to be carcinogenic in small experiments. All the analogues which
are known to have hypomethylating activity were found to be cytotoxic in vitro; the most potent being
5-azacytidine. As judged by decreased rat weight compared to untreated controls, the fluorinated cytidine
analogues and 5'-deoxyazacytidine were more toxic than 5-azacytidine. Altered haemoglobin synthesis was
seen in rats and DBA/2J mice, but not in sheep. In mice, where the clearest haemoglobin changes were noted,
an increase in minor haemoglobin synthesis was found using both high and low doses of 5-azacytidine, and
with 5,6-dihydro-5-azacytidine and 5-aza-2'-deoxycytidine. These last two analogues appear to be relatively
non-toxic, noncarcinogenic in these experiments, and retain haemoglobin activating properties with a potency
similar to that of 5-azacytidine.
Enzymatic DNA methylation occurs as a postreplicative
process, producing, in mammals, only the minor base 5-
methylcytosine. The methylation of specific DNA cytosine
residues is inversely correlated with transcription of most
genes, although there are exceptions. Inhibitors of DNA
methylation will often activate previously silent genes and
this is the strongest single line of evidence implicating
methylation in gene control. There have been several recent
reviews of mammalian DNA methylation (Holliday, 1979;
Riggs & Jones, 1983; Nyce et al.,1983; Doefler, 1983; Razin
et al., 1984; Jones, 1986), and considering all data, it appears
that methylation of DNA cytosine is one among several
mechanisms significant in the control of mammalian gene
expression (Riggs & Jones, 1983; Doefler, 1983; Razin et al.,
1984), perhaps functioning primarily as a locking mechanism
for the stable maintenance of the transcriptionally silent state
(Razin & Riggs, 1980).
There has been speculation that DNA methylation
changes may play some role in tumour initiation or pro-
gression (Holliday, 1979; Riggs & Jones, 1983; Nyce et al.,
1983; Jones, 1986), and some experimental data are now
available. Evidence that DNA methylation changes may be
associated with tumorigenesis is as follows: (a) The DNA of
tumour cells has often been found to be undermethylated
compared to the DNA of normal cells (although exceptions
have been found) (Lapeyre et al., 1981; Gama-Sosa et al.,
1983; Goelz et al., 1985); the methylation patterns of some
genes that are expressed in tumour cells have been found to
be altered in association with increased gene expression
(Feinberg & Vogelstein, 1983a,b; Cheah et al., 1984); (b) the
DNA of tumour metastases is less-methylated than the DNA
of primary tumours (Gama-Sosa et al., 1983); (c) the DNA
of primary malignant tumours is less-methylated than the
DNA of benign tumours (Gama-Sosa et al., 1983); (d)
transformed cells have been shown to have their metastatic
properties altered by the potent inhibitor of DNA
methylation, 5-azacytidine (Olsson & Forchammer, 1984;
Trainer et al., 1985; Ormerod et al., 1986); (e) several
carcinogens have been shown to cause demethylation
(Boehm & Drahovsky., 1979, 1981; Salas et al., 1979; Wilson
& Jones, 1983); (f) 5-azacytidine, an inhibitor of DNA
methylase, has been shown to be a carcinogen in some
experimental animal studies (Denda et al., 1985; Stoner et
al., 1973; National Cancer Institute 1978; Carr et al., 1984;
Vesely & Cihak, 1973).
5-Azacytidine, an analogue of cytidine in which a nitrogen
atom replaces the carbon at position 5 in the pyrimidine
ring, was synthesized as an anti-cancer agent (Piskala &
Sorm, 1964). Its known toxicities include immunosup-
pression, teratogenicity, abortifacient activity and gastro-
intestinal toxicities, and its biological effects include an
inhibition of cell growth and liver regeneration (Cihak, 1974;
Hrodek & Vesely, 1971; Weiss et al., 1972; Cihak & Vesely,
1969), alteration of protein synthesis (Reichman & Penman,
1973), gene activation (Nyce et al., 1983), and alteration of
the differentiation properties of cells (Constantinides et al.,
1977, 1978). Recent interest in this drug has centered both
on its ability to alter gene activity, and thus its use as a
probe in understanding gene regulation, and also on its
clinical applications in the induction of otherwise silent genes
in the treatment of humans with sickle cell anaemia
(Charache et al., 1983), ,B+thalassemia (Ley et al., 1982) and
its potential in the treatment of other heritable diseases. In
preliminary experiments, we recently observed that 5-
azacytidine might be a complete carcinogen in the F344 rat
(Carr et al., 1984) and might also have hepatic tumour
promoting activities. In view of the possible application of 5-
azacytidine both in the treatment of human malignancies as
well as its potential applicability in chronic treatment of
humans with non-malignant diseases, we investigated the
carcinogenicity of 5-azacytidine in a much larger series of
animals and in lower doses. In addition, we also examined
other cytidine analogues with known hypomethylating and
gene activating properties (Jones & Taylor, 1980), in the
hope of finding an analogue that might retain the gene
activating without the carcinogenic properties.
Materials and methods
Experimental animals
Male F344 rats (Simonsen Labs Inc., Gilroy, CA) were fed a
basal diet (Purina Lab Chow) and maintained on a 12-h
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light cycle with unlimited access to food and water, ac-
cording to the 'Guide to the Care and Use of Laboratory
Animals', NIH Publication 85-23. For regimens 1-10, and
13 and 14 (Table I) young adult male rats, at initial weight
160-180g were injected i.p. thrice weekly with either 0.9%
NaCl solution (controls) or test drug solution that was
freshly dissolved in NaCl 0.9% solution immediately before
each injection. Rats were weighed alternate weekly as a guide
to their well being. At the end of the experments, rats were
sacrificed and the organs were examined grossly, then
examined microscopically after fixation. For the study of
transplacental carcinogenesis (Regimen 11) pregnant female
rats were injected on day 21 of timed pregnancies. Male
weanling rats were injected once only 21 days after birth
(Regimen 12).
Pathological evaluation
A routine gross post mortem examination was performed on
all rats at the time of sacrifice. Microscopic examination was
performed on a sample of each of the major organs that was
taken for fixation in 10% neutral buffered formalin. The
tissue specimens were subsequently embedded in paraplast,
sectioned at 4,um and stained with hematoxylin and eosin.
Histological sections from the organs of all rats were
examined blindly fashion by one of the authors (CDW)
according to previously-described criteria (Stewart et al.,
1959, 1980). Selected samples, including the livers were
subjected to outside pathological review.
Statistical evaluation ofresults
The data were evaluated for significance using the Fisher's
exact test for equality of proportions, with correction for
multiple comparisons.
Experimental protocols (Table I)
Rats were injected i.p. 3 times weekly with either 0.9% NaCl
solution (Regimen 1) or with one of 3 doses of 5-azacytidine,
(Regimens 2, 3, 4) starting at a dose of 2.5mgkg-1. These
doses were 2.5 (Regimen 2), 0.25 (Regimen 3), and
0.025 mgkg- 1 (Regimen 4). The following cytidine analogues
were used at the highest dose used for 5-azacytidine
(2.5mgkg-1): 5-aza-2'-deoxycytidine (Regimen 5), 5-fluoro-
2'-deoxycytidine (Regimen 6), 5-fluorocytidine (Regimen 7),
5,6-dihydro-5-azacytidine (Regimen 8), and 6-azacytidine
(Regimen 9). In order to determine whether cytidine in 10-
fold excess concentration would compete with 5-azacytidine,
cytidine at 25mgkg-1 was administered at the same time as
5-azacytidine (Regimen 10). 5-azacytidine was administered
once only at day 21 to timed pregnant rats at a dose of
10mgkg (Regimen 11) or once only at a dose of
5 mgkg to weanling rats (Regimen 12). In order to
determine whether 5-azacytidine had hepatic tumour
promoting activity, rats were administered a liver cancer
initiating dose of diethylnitrosamine 30 mgkg-1 administered
18 h after a partial hepatectomy, after the regimen of Pitot et
al. (1978), and were then given chronic 5-azacytidine
2.5 mgkg-1 i.p. as in regimen 2. Two control regimens were
used. Firstly, age controls (Regimen 1) in which rats were
administered 0.5ml NaCl 0.9% i.p. three times weekly, or
tetrahydrouridine 27.5mgkg-1 three times weekly (Regimen
14). Because of the deamination of 5-azacytidine and its
analogue in vivo by cytidine deaminase (Chabner et al.,
1973), unstable analogues (Regimens 5,6,7,8) were ad-
ministered together with tetrahydrouridine (THU) (Neil et
al., 1970), 27.5mgkg-1, by a separate intraperitoneal in-
jection at the same time as each injection of 5-azacytidine.
Haemoglobin studies. (a) Sheep were chosen because of
the presence of developmentally-regulated haemoglobin
switching (Young et al., 1978). Two 4-month old female
Rambole X Hampshire sheep 60-65 lb wt were purchased
and were both bled 100ml and injected daily through the
jugular vein with 5-azacytidine 2mgkg-1 for 5 days out
of 7. Weekly haemoglobin estimations were performed.
Haemoglobin electrophoreses were done using cellulose
acetate pH 8.6 (Jones & Taylor, 1980). (b) DBA/2J female
mice 6-8 gwt (Jackson Laboratory, Bar Harbor, Maine)
were chosen because of the presence of a clearly identifiable,
inducible minor haemoglobin (Alter et al., 1982). They were
injected twice weekly i.p. with one of the following:
5-azacytidine 16 or 1.6mgkg-1, 5,6-dihydro-5-azacytidine
6mgkg-1, 5-aza-2'-deoxycytidine 16mgkgi- plus tetra-
hydrouridine, or NaCl 0.9% (controls). The mice were bled
twice weekly and haemoglobin components were separated
by cellulose acetate electrophoresis as well as by DEAE
cellulose-chromatography (Isolab Inc., Akron, OH). The 2
haemoglobin bands were eluted and separately measured
spectrophotometrically. (c) Male F344 rats 160-180gwt
were injected twice weekly with 5-azacytidine 2.5mgkg-1
and bled intermittently (Regimen 2, Table I). The haemo-
globins were separated by cellulose acetate electrophoresis,
pH 8.6 (Titan III-H, Helena Labs, Beaumont, TX) and
the 5 bands were quantitated using scanning densitometry
(Garrick et al., 1975).
Cytotoxicity assays. Primary monolayer cultures of
hepatocytes from male F344 rats 160-180 gwt were prepared
as we have previously described (Carr & Laishes, 1981). After
a 3 h attachment period using Leibowitz L-15 medium
(GIBCO Labs, Grand Island, NY) and 10% calf serum, the
medium was changed to fresh medium containing 10% calf
serum and the cells were then incubated without (controls)
or with various cytidine analogues at the indicated doses.
After a 24h incubation period in vitro, trypan blue was
added to the tissue culture cells and the percentage of suvival
was assessed. Cell survival was measured as the percentage
viable attached cells in the experimental flasks compared to
the percent viable attached cells in the control of flasks.
Reagents. Chemicals used were: 5-azacytidine and 5-aza-2'-
deoxycytidine (Sigma Chemical Company, St Louis, MO); 6-
azacytidine, 5-fluoro-2'-deoxycytidine and 5-fluorocytidine
(Calbiochem); 5,6 dihydro-5-azacytidine and tetrahydrouri-
dine were a gift from the Drug Synthesis and Chemistry
Branch of the National Cancer Institute, NIH, Bethesda,
MD. 5-fluorocytidine was synthesized by Calbiochem-
Behring (San Diego, CA); pseudoisocytidine for use in tissue
culture was a kind gift of Dr J.J. Fox, Laboratory of
Organic Chemistry, Sloan-Kettering Institute for Cancer
Research, Rye, New York.
Results
Carcinogenicity
We investigated the carcinogenicity of 3 doses of 5-
azacytidine, using 2.5, 0.25, and 0.025mgkg-1. The highest
dose chosen was the lowest dose that appeared to be
carcinogenic in a preliminary experiment (Carr et al., 1984).
A large excess of rats was used for the 5-azacytidine
compared to the control regimen (Regimens 1 and 2, Table
I) in anticipation of a steady attrition rate at this dose of 5-
azacytidine. However, attrition was low and 87% survived.
Table II shows that 18% of the rats treated with the highest
dose of 5-azacytidine developed non-testicular tumours
compared to none in the control group (Regimen 2, Table
II). In this group, 6 of the 87 evaluable rats also had
histological evidence of intraperitoneal fat necrosis. No rats
developed tumours at the lower doses of 5-azacytidine
(Regimens 3 and 4, Table II). While 20% of the control rats
developed testicular tumours, particularly of the Leydig cell
type, as has been reported elsewhere as a feature of aging
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TableI Treatment regimens
Regimen Treatment type Dose Route Frequency Duration
1. Age controls: NaCl 0.9% 0.5ml i.p. 3 x weekly 1 yr
2. 5-azacytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
3. 5-azacytidine 0.25mgkg-1 i.p. 3 x weekly 1 yr
4. 5-azacytidine 0.025mgkg-1 i.p. 3 x weekly 1 yr
5. 5-deoxyazacytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
+THUb27.5mgkg-1
6. 5-fluorodeoxycytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
+THU 27.5mgkg-1
7. 5-fluorocytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
+THU 27.5mgkg- 1
8. 5,6-dihydro-5-azacytidine 50mgkg- 1 i.p. 3 x weekly 1 yr
9. 6-azacytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
10. 5-azacytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
+cytidine 25mgkg- 1 i.p. 3 x weekly 1 yr
11. 5-azacytidine at day 21 10mgkg-I i.p. to once a
to timed pregnant rats mother
12. 5-azacytidine to 25g 5mgkg- i.p. once d
weanling rats
13. PH/DENC 30mgkg1 i.p. once
5-azacytidine 2.5mgkg-1 i.p. 3 x weekly 1 yr
14. THU 27.5mgkg-
I i.p. 3 x weekly lyr
aOffspring examined 1 yr after birth; bTHU, Tetrahydrouridine; CPH, 2/3 Partial
Hepatectomy; DEN, Diethylnitrosamine 18h after PH; dRats examined 1 yr after birth.
Table II Carcinogenicity study of 5-azacytidine and analogues in male F344 rats: Overall results
No. rats No. rats
No. rats with non- with testis % rats No. rats with
testis tumours tumours with any Leydig cell
Category treatment Initial Evaluablea (%) P (%) P tumour hyperplasia
1. Controls 50 49 0 10(20) 20% 6
2. 5-azacytidine 2.5mgkg 1 100 87 16(18) <0.01 56(64) <0.001 72% 11
3. 5-azacytidine 0.25mgkg 1 10 10 0 2(20) NS 20%
4. 5-azacytidine 0.025mgkg1 10 10 0 1 (10) NS 10%
5. 5-deoxyazacytidine+THU 10 10 0 0 0 2
6. 5-fluorodeoxycytidine+THU 10 10 0 1(10) NS 10% 2
7. 5-fluorocytidine+THU 10 10 0 0 0 2
8. 5,6-dihydro-5-azacytidine 10 9 1 (11) 0.12 2(22) NS 33% 1
9. 6-azacytidine 15 12 0 2(17) NS 17% 9
10. 5-azacytidine+cytidine 10 5 0 2(40) NS 40%
11. 5-azacytidine to 5 pregnant rats 22 22 3(14) 0.03 3/13 (23) NS 27% 3/13
(offspring: 13 male, 9 female)
12. 5-azacytidine to weanlings 10 9 1(11) NS 2(22) NS 33% 6
13. PH/DEN-.5-azacytidine 10 8 5(63) <0.001 1(13) NS 75%
(8/8 hyperplastic
liver nodules)
14. THU (controls) 10 10 0 3(30) NS 30% 5
PH, Partial hepatectomy; DEN, diethylnitrosamine 30mgkg-1 i.p. 18h after PH; THU, tetrahydrouridine; NS, not significantly different
from control values; P using Fisher's exact test; aEvaluable, no. of rats surviving till end of experiment.
testicular tumours were seen in the group treated with
2.5mgkg-1 5-azacytidine (Regimen 2, Table II). The doses
for the analogues were 10% of the LD1O dose, obtained in
preliminary experiments, except for 5,6-dihydro-5-azacyti-
dine, for which no practicable LD50 dose could be found.
No excess of non-testicular tumours was seen with any of
the analogues. In the 5,6-dihydro-5-azacytidine group, one
rat developed a sarcoma but this was not statistically
significant (Regimen 8, Tables II & III) and a single rat had
intraperitoneal fat necrosis. It was interesting that in the
group of rats treated with 5'-deoxyazacytidine (Regimen 5,
Table II), all 10 developed testicular atrophy, characterized
by reduction in size of seminiferous tubules secondary to
absence of spermatogenesis, and the presence of oedema and
focal interstitial fibrosis. Two of the 10 also showed Leydig
cell hyperplasia. In a small group of rats treated with 5-
azacytidine plus a 10-fold concentration of cytidine (Regimen
10, Table 2) no excess of nontesticular tumours were noted.
In the group of rats that received a single initiating dose of
the liver carcinogen DEN (Regimen 13, Table II), all the
surviving rats developed hyperplastic liver nodules and a
high incidence of non-hepatic, non-testicular primary
tumours. Previous work has established that low single DEN
doses after a two-thirds partial hepatectomy do not result in
liver tumours without subsequent tumour promotion (Carr
et al., 1984; Pitot et al., 1978). Tetrahydrouridine control
rats did not develop any excess of non-testicular tumours
nor did they show testicular atrophy (Regimen 14). In a test
for transplacental carcinogenicity, timed pregnant rats were
given a single large dose of 5-azacytidine on the last day of
their pregnancy. Earlier periods were not used because of the
known fetotoxicity of 5-azacytidine (Schmahl et al., 1985 and
our unpublished data). A high incidence of non-testicular
primary tumours was noted (3 male, 1 female) but no excess
of testicular tumours was found (Regimen 11, Table II).
When 5-azacytidine was given as a single dose to weanling
rats (Regimen 12, Table II), a single rat developed a non-
testicular tumour.398 B.I. CARR et al.
Spectrum of tumour types
The sepctrum of primary tumour types that was induced in
response to chronic administration for the various cytidine
analogues is shown in Table III. Tumours were those of the
lymphoid system, kidney, lung, skin at the site of injection,
sarcomas and mesotheliomas. Hyperplastic liver nodules
were found in the rats which were treated with 5-azacytidine
after a single initiating dose of the hepatic carcinogen
diethylnitrosamine (Regimen 13, Table III).
Cytotoxicity ofcytidine analogues
Using a primary monolayer culture system of freshly isolated
normal rat hepatocytes to test the cytocidal effects of the
cytidine analogues, the cytotoxic actions of the drugs used in
the carcinogenicity study were compared (Table IV). The
analogues were incubated with or without the deaminase
inhibitor tetrahydrouridine. The results are shown for
incubations without tetrahydrouridine, but they were ident-
ical in the presence of tetrahydrouridine. The most toxic
analogue was 5-azacytidine, followed by 5-fluorocytidine and
5,6-dihydro-5-azacytidine. In this assay, differences of less
than 10% are not considered significant. The changes in rat
weights over the duration of the experiment with the
different analogues are shown in Figure 1.
Minor haemoglobin induction by cytidine analogues.
The ability of cytidine analogues to induce minor
haemoglobin synthesis was investigated using 3 different
mammalian species: sheep, rats and mice. Advantage was
taken of the fact that in sheep and mice, the induction
of an otherwise silent or minor haemoglobin can be
unambiguously demonstrated. DBA/2J mice were chosen
following the report that this inbred strain has a minor
haemoglobin comprising -20% of the total haemoglobin, is
electrophoretically distinct, and increased synthesis is
inducible by an anaemic stress (Alter et al., 1982). Another
species with a foetal haemoglobin switch which is capable of
induction is the sheep (Young et al., 1978). Figure 2 shows
the patterns of haemoglobin electrophoresis in the 3 species,
sheep, rats and mice. Chronic administration of 2.0mgkg-'
5-azacytidine to 2 sheep for 4 months resulted in no
induction of the minor haemoglobin (Figure 2c, d). However,
rats in the carcinogenicity studies of this report, showed
qualitative changes with the 5-azacytidine doses used (Figure
2e-g). An increase was found in the 2 anodic of the 5 total
haemoglobin bands that were visualized on the cellulose
acetate electrophoretograms and the disappearance of one
band. However, no unambiguous rat haemoglobin changes
were seen with any of the other analogues. The significance
of the multiple rat haemoglobins is not clear, since they have
not been characterized, to our knowledge. In the DBA/2J
mice, a greater than 30% increase (Table V) in the minor
haemoglobin component was seen in 8 of 9 mice treated with
5-azacytidine 1.6mgkg-1, in 6 of 10 mine treated with 5,6-
dihydro-5-azacytidine 1.6mgkg-1, and in 2 of 5 mice treated
with 5-aza-2'-deoxy-5-azacytidine 1.6mgkg-1. No significant
increase in the minor haemoglobin was seen in the saline
controls or the mice treated with 6-azacytidine.
Table VI shows the cytidine analogues that were used in
this study, and compares their reported activity as inhibitors
of methylation in vitro with their activity as complete
carcinogens and inducers of haemoglobin synthesis. No clear
relationship between the potency of the analogues as in-
hibitors of DNA methylation and their action as carcinogens
is apparent.
Discussion
The aims of this study were to investigate the carcino-
genicity, toxicity and the haemoglobin activating properties
of 5-azacytidine, and to initiate the evaluation of some
related analogues to determine whether there was a safer and
less toxic analogue that might retain the gene activating
properties. The results of this study were severalfold: (1) we
confirmed that 5-azacytidine is a complete carcinogen for
several tissues and a probable tumour promoter for liver; (2)
none of the other analogues tested were significantly
carcinogenic, although the sample size was small; (3) a single
dose of 5-azacytidine delivered transplacentally to neonates
was carcinogenic; (4) several analogues induced minor
haemoglobin synthesis in mice, keeping open the possibility
that minor haemoglobin induction and carcinogenicity are
not irrevocably linked; and (5) only 5-deoxyazacytidine
caused dramatic testicular atrophy.
In the main carcinogenicity study of this report, in which
5-azacytidine 2.5mgkg-1 given over 12 months was
compared to age-matched control rats (Regimens 1 and 2,
Table II), we found that 5-azacytidine induced both a 3-fold
increase in the incidence of testicular tumours over the
spontaneous incidence which occurs in normal rats with age
(Goodman et al., 1979), and also a large increase in the
incidence of non-testicular tumours. In addition, we were
able to confirm our preliminary observation that 5-
azacytidine appears to enhance the induction of hyperplastic
(neoplastic) liver nodules in rats that were treated with a
single initiating dose of diethylnitrosamine. Thus, it appears
to be a tumour promoter in the liver. We did not find any
significant carcinogenic activity of the cytidine analogues
which we tested. The concomitant administration of cytidine
with 5-azacytidine did not appear to suppress the increased
Table III Organ distribution of tumours
Hyperplastic
Regimens (No. rats) Lymphoma Renal Lung Skin Mesothelioma Sarcoma Testis liver nodules
1. Controls (49) 10
2. 5-azacytidine 2.5mgkg 1 (87) 4 4 1 3 2 2 56
3. 5-azacytidine 0.25mgkg 1 (10) 2
4. 5-azacytidine 0.025mgkg-1 (10) 1
5. 5-deoxycytidine+THU (10)
6. 5-fluorodeoxycytidine+THU (10) 1
7. 5-fluorocytidine+THU (10)
8. 5,6-dihydro-5-azacytidine (9) 1 2
9. 6-azacytidine (12) 2
10. 5-azacytidine+cytidine (5) 2
11. 5-azacytidine to 5 pregnant rats
(offspring: 13 male, 9 female) 1 1 1 3 1
12. 5-azacytidine to
weanlings (9) 1 2
13. PH/DEN-.5-azacytidine (8) 2 3 1 8
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Table IV Cytotoxicity ofcytidine analogues
Treatmenta % Survival'
Tetrahydrouridine 100
Cytosine 85+4
Cytidine 77+6
Pseudoisocytidine 70+7
5-fluorocytosine 69+6
6-azacytidine 67+5
5-aza-2'-deoxycytidine 63+4
5-fluoro-2'-deoxycytidine 62+8
5,6-dihydro-5-azacytidine 50+7
5-fluorocytidine 47+ 11
5-azacytidine 32+8
aAll drugs were incubated with freshly-
isolated attached normal hepatocytes in vitro
at 1 x 10-4M for 24h. 5-azacytidine and its
analogues were incubated with or without tetra-
hydrouridine 1 x 10-3 M. Tetrahydrouridine
alone was used at 1 x 10-3 M; b% survival= %
attached, viable cells in treatment flasks/attached
viable cells in control flasks without test toxin,
using trypan blue exclusion assay.
I
40
44-
o 1 2 3 4 5 6 7 8 9 10 11 12
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Figure 1 Effects of chronic administration of cytidine analogues
on rat weights. Rats were chronically administered cytidine
analogues intraperitoneally in 0.9% NaCl solution (experiments)
or NaCl solution only (controls). The regimens were as in
Table I, and the rats were weighed monthly. The datum points
are averages for all the rats in each regimen; controls (0);
5-azacytidine (-); 5-fluorocytidine +THU (0); 5-
deoxyazacytidine +THU (A); 5-fluorodeoxycytidine +THU (El);
5,6-dihydro-5-azacytidine (A).
number of testis tumours, although non-testicular tumours
were not seen in a small series (Regimen 10, Table I). It was
of great interest however, that 5-azacytidine induced
transplacental carcinogenesis of non-testicular tumours
(Regimen 11, Table I). In another report, 5-azacytidine was
found to induce transplacental carcinogenesis in mice
(Schmahl et al., 1985).
The results of 5-azacytidine action are expected to be
complex. On the one hand, 5-azacytidine is capable of
enhancing or inducing the metastatic capacity of various
tumour cell lines (Olsson & Forchammer, 1984; Trainer et
al., 1985; Ormerod et al., 1986), activating silent retroviral
genomes (Jaenisch et al., 1985), enhancing the induction by
various carcinogens of gamma-glutamyltransferase positive
liver foci (Denda et al., 1985), of altering cellular DNA
which is incapable of inducing transformation (Venolia et
al., 1982), and of inducing tumorigenesis in various cells in
culture (Venolia et al., 1982; Harrison et al., 1983; Benedict
et al., 1977; Marquardt & Marquardt, 1977), even though it
does not appear to be a significant mutagen in mammalian
cells (Landolph & Jones, 1982; Frost et al., 1984; Momparler
et al., 1984; Delers et al., 1984; Bouck et al., 1984; Jones,
1984). On the other hand, 5-azacytidine has been shown to
induce differentiation in both non-transformed as well as in
neoplastic cells in culture (Constantinides et al., 1977, 1978;
Jones & Taylor, 1980; Walker et al., 1984; Creusot et al.,
1982; Darmon et al., 1984; Pinto et al., 1984). 5-Azacytidine
is a cell toxin and has been used to treat leukaemia (von
Hoff et al., 1976) and can induce the expression of new cell
surface antigens and thus increase the effectiveness of
immunosurveillance in immunocompetent animals (Frost et
al., 1984). Thus, there appear to be opposite sets of
biological actions with respect to carcinogenicity. The
explanation may reside in the net effect of the genes that are
activated by 5-azacytidine under a given set of experimental
conditions. We did not find any evidence of carcinogenicity
for 5-azacytidine at log doses below 2.5mgkg-1 in rats. The
spectrum of tumour types were similar to that seen
previously (Carr et al., 1984; Schmahl et al., 1985); viz.,
tumours of the lymphoid system, skin, lung and kidney, as
well as sarcomas and mesotheliomas (Table III). The skin
tumours occurred only at the site of injection, suggesting
that there was no need for further drug processing for the
carcinogenic action to occur.
Two assays for toxicity were used in our experiments. The
first was the change in rat weights with time during the
carcinogenicity studies (Figure 1). Very few rats died during
the experiment and most weight loss was found for the rats
treated with the fluorinated cytidine derivatives and with 5-
deoxyazacytidine. The second assay was a 24h cytotoxicity
study using primary monolayer cultures of freshly prepared
normal hepatocytes (Table V). The 3 drugs with most
cytotoxic effects were 5-azacytidine,. 5-fluorocytidine and 5,6-
dihydro-5-azacytidine. The addition of tetrahydrouridine to
the analogues in cell culture did not influence the toxicity.
The electrophoretic pattern of haemoglobin components of
rats was quite complicated and 5 major haemoglobins were
visualized, with several minor bands appearing on the
densitometry tracings of the electrophoretograms. The
changes included an increase in density in the 2 anodic bands
and an almost complete disappearance of a third
haemoglobin band (Figure 2e-g). As a result of the
complexities inherent in interpreting the multiple
haemoglobin bands in rat blood, 2 other species with well-
studied and less complicated haemoglobin bands were used.
No minor haemoglobin component induction was found in
the 2 sheep that were used. However, DBA/2J female mice
which have a major and a minor haemoglobin, showed an
increased synthesis of the minor haemoglobin at both high
and low doses of 5-azacytidine. This increased minor
haemoglobin synthesis in mice was also induced by 5,6-
dihydro-5-azacytidine and 5-aza-2'-deoxycytidine (Table V).
Interestingly, increased minor haemoglobin synthesis did not
take place within the first few days of cytidine analogue
treatment of the mice, but appeared slowly over a 2 month
period. Similarly, 5,6-dihydro-azacytidine induces an increase
in foetal haemoglobin in humans (Carr et al., 1987). The
mechanism by which cytidine analogues alter minor
haemoglobin synthesis is not entirely clear. Although gene
activation through DNA methylation changes is a candidate
mechanism, other possibilities exist, such as erythroid pool
stress. Although we did not observe haematocrit decreases of
more than 20%, subtle erythroid stress cannot be excluded.
On comparing the results for minor haemoglobin
induction (Table IV) with the carcinogenicity results (Table
II), it appeared that 5-azacytidine was able to induce an
increased minor haemoglobin synthesis in mice and altered
haemoglobin synthesis in rats at lower doses than were
required for the induction of rat tumours. However, it
cannot be assumed that mouse and rat tumorigenic doses
will be the same, and separate carcinogenicity studies will be
required for the mouse. Two analogues appeared to have
haemoglobin activating properties similar to those observed400 B.I. CARR et al.
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Figure 2 Electrophoretic separation of haemoglobins of mice, sheep and rats treated with or without 5-azacytidine. Lanes
a and b, cellulose acetate electrophoresis at pH 8.6 of peripheral blood haemoglobins from DBA/J female mice treated (a) with or
(b) without 5-azacytidine 1.6mgkg-1 for 60 days. The horizontal arrow by lane a indicates the induced band. Lanes c and d,
cellulose acetate electrophoresis at pH 8.6 of sheep blood hasmoglobins; (c) pretreatment; (d) after 4 months of 5-azacytidine
2.0mgkg-1 treatments. Lanes e, f, and g, cellulose acetate electrophoresis at pH 8.6 of peripheral blood haemoglobins from male
F344 rats: (e) normal controls, (f,g), 5-azacytidine (2.5mgkg-1) treated rats after 60 days. The vertical arrow shows the direction
of electrophoresis; 0, indicates the origin, to show anodic and cathodic migration of rat haemoglobin bands. The 4 horizontal
arrows by lane e indicate, in descending order: two normal cathodic bands which are increased by 5-azacytidine; precipitated
haemoglobin at the origin (heavy band above plane of the gel); the normal anodic band which decreases with 5-azacytidine
treatment.
Table V Effects ofcytidine analogues on minor haemoglobin synthesis in DBA/2J mice
Minor Hb as % total Hb (mean+s.d.)
% increase over control
Analogue Initial 30 days 60 days minor Hb at 60 days
Controls (n =8) 14.8+0.6 15.3+2.0 16.3+ 1.8
6-azacytidine (n=5) 14.3+0.7 14.9+ 1.4 15.6+ 1.5
5-azacytidine 16mgkg1 (n=10) 14.5+1.5 17.0+1.9 22.2+4.2 36
5-azacytidine 1.6mgkg-1 (n=9) 15.6+1.3 15.3+5.8 21.7+3.8 33
5,6-dihydro-5-azacytidine 1.6mgkg-1 (n=10) 14.2+3.6 25.0+3.1 24.7+ 1.8 52
5-aza-2'-deoxycytidine 1.6mgkg-1 (n=5) 14.3+ 1.4 16.4+2.4 21.3+0.7 31
Table VI Inhibition of DNA methylation and carcinogenesis
Human
Inhibition of Carcinogenic Mouse minor foetal Hb
Analogue methylationa activityb Hb synthesisc synthesis
6-azacytidine - - - ND
5-azacytidine + + + + + + + +d
5-aza-2'-deoxyazacytidine + ++ - + ND
5-fluorocytidine ND - ND ND
5-fluorodeoxycytidine + + - ND ND
5,6-dihydro-5-azacytidine - + + + e
aIn vitro data (abstracted from Jones & Taylor, 1980, Table I); 'This paper, Table II; cThis
paper, Table IV; dLey et al. (1982); Charache et al. (1983); eCarr et al. (1987); ND Not done.
for 5-azacytidine, viz., 5,6-dihydro-5-azacytidine and 5-aza-
2',deoxycytidine. These two analogues had no significant
carcinogenic activity in our study. 5-aza-2'-deoxycytidine
appears particularly promising in this respect, since it was of
only moderate toxicity (Table V and Figure 1) and did not
induce tumours in a small carcinogenicity series, yet retained
gene activating properties. These results confirm that 5-
azacytidine is a complete carcinogen in the male F344 rat,
and show that it has transplacental carcinogenic properties,
and can act as a hepatic tumour promoter. No 5-azacytidine-
induced tumorigenicity was seen below 2.5mgkg-1 in our
study. 5-Azacytidine was'able to alter haemoglobin synthesis
in rats and mice. Five other cytidine analogues were also
tested for carcinogenicity in experiments with low numbers
of rats, in which tumorigenicity was not clearly demon-
strable. However, 2 of these apparently non-carcinogenic
analogues, 5,6-dihydro-5-azacytidine and 5-aza-2'-
deoxycytidine retained the ability to increase minor
haemoglobin synthesis. These results suggest that it may be
possible to separate the carcinogenic from the potentially
useful gene-activating properties' in some cytidine analogues.
From the results reported here and elsewhere (Table VI)
there does not appear to be a clear relationship among
cytidine analogues between potency as inhibitors of DNA
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